Review



tumor mutational profiles  (Caris Life Sciences)

 
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 86
      Buy from Supplier

    Structured Review

    Caris Life Sciences tumor mutational profiles
    (A) <t>Mutational</t> frequencies of the top mutated genes identified in the 72 non‐hypermutated gastric cancer (GC) tumors from PRH ( n = 72 for all genes except ARID1A ( n = 62), KMT2D ( n = 70), MYH11 ( n = 63), IRS2 ( n = 65), and CLTCL1 ( n = 61)). (B) Mutational frequencies by anatomical location of non‐hypermutated GC tumors from PRH. For Fundus/Cardia, there were 13 cases, and n = 13 for all genes, except for MYH11 , PHOX2B , and PER1 , which had n = 12. For the Body, there were 45 cases, and all genes had n = 45, except for ARID1A ( n = 38), KMT2D ( n = 43), and CACNA1D ( n = 39). For the Antrum, there were 14 cases, and all genes had n = 14, except for NOTCH1 ( n = 12), CDKN2A ( n = 13), and NFE2L2 ( n = 13).
    Tumor Mutational Profiles, supplied by Caris Life Sciences, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/tumor+mutational+profiles/comprehensive+molecular+profiling/pmc12420367-92-2-16
    Average 86 stars, based on 1 article reviews
    tumor mutational profiles - by Bioz Stars, 2026-10
    86/100 stars

    Images

    1) Product Images from "Actionable Genes and Carcinogenic Pathways for Gastric Cancer in Latinos"

    Article Title: Actionable Genes and Carcinogenic Pathways for Gastric Cancer in Latinos

    Journal: Cancer Medicine

    doi: 10.1002/cam4.71216

    (A) Mutational frequencies of the top mutated genes identified in the 72 non‐hypermutated gastric cancer (GC) tumors from PRH ( n = 72 for all genes except ARID1A ( n = 62), KMT2D ( n = 70), MYH11 ( n = 63), IRS2 ( n = 65), and CLTCL1 ( n = 61)). (B) Mutational frequencies by anatomical location of non‐hypermutated GC tumors from PRH. For Fundus/Cardia, there were 13 cases, and n = 13 for all genes, except for MYH11 , PHOX2B , and PER1 , which had n = 12. For the Body, there were 45 cases, and all genes had n = 45, except for ARID1A ( n = 38), KMT2D ( n = 43), and CACNA1D ( n = 39). For the Antrum, there were 14 cases, and all genes had n = 14, except for NOTCH1 ( n = 12), CDKN2A ( n = 13), and NFE2L2 ( n = 13).
    Figure Legend Snippet: (A) Mutational frequencies of the top mutated genes identified in the 72 non‐hypermutated gastric cancer (GC) tumors from PRH ( n = 72 for all genes except ARID1A ( n = 62), KMT2D ( n = 70), MYH11 ( n = 63), IRS2 ( n = 65), and CLTCL1 ( n = 61)). (B) Mutational frequencies by anatomical location of non‐hypermutated GC tumors from PRH. For Fundus/Cardia, there were 13 cases, and n = 13 for all genes, except for MYH11 , PHOX2B , and PER1 , which had n = 12. For the Body, there were 45 cases, and all genes had n = 45, except for ARID1A ( n = 38), KMT2D ( n = 43), and CACNA1D ( n = 39). For the Antrum, there were 14 cases, and all genes had n = 14, except for NOTCH1 ( n = 12), CDKN2A ( n = 13), and NFE2L2 ( n = 13).

    Techniques Used:

    Frequency of genetic alterations in key signaling pathways in non‐hypermutated gastric cancer cases leading to deregulation of the WNT/β‐catenin, MAPK, PI3K, TGF‐β, and p53 signaling pathways in the non‐hypermutated cases. The frequencies of alterations are expressed as a percentage of all cases. The red color denotes the overall mutational frequency, and blue denotes the amplification frequency for each gene. Figure adapted from: Nature, volume 487, pages 330–337 (2012).
    Figure Legend Snippet: Frequency of genetic alterations in key signaling pathways in non‐hypermutated gastric cancer cases leading to deregulation of the WNT/β‐catenin, MAPK, PI3K, TGF‐β, and p53 signaling pathways in the non‐hypermutated cases. The frequencies of alterations are expressed as a percentage of all cases. The red color denotes the overall mutational frequency, and blue denotes the amplification frequency for each gene. Figure adapted from: Nature, volume 487, pages 330–337 (2012).

    Techniques Used: Protein-Protein interactions, Amplification



    Similar Products

    tumor mutational profiles  (Caris Life Sciences)
    86
    Caris Life Sciences tumor mutational profiles
    (A) <t>Mutational</t> frequencies of the top mutated genes identified in the 72 non‐hypermutated gastric cancer (GC) tumors from PRH ( n = 72 for all genes except ARID1A ( n = 62), KMT2D ( n = 70), MYH11 ( n = 63), IRS2 ( n = 65), and CLTCL1 ( n = 61)). (B) Mutational frequencies by anatomical location of non‐hypermutated GC tumors from PRH. For Fundus/Cardia, there were 13 cases, and n = 13 for all genes, except for MYH11 , PHOX2B , and PER1 , which had n = 12. For the Body, there were 45 cases, and all genes had n = 45, except for ARID1A ( n = 38), KMT2D ( n = 43), and CACNA1D ( n = 39). For the Antrum, there were 14 cases, and all genes had n = 14, except for NOTCH1 ( n = 12), CDKN2A ( n = 13), and NFE2L2 ( n = 13).
    Tumor Mutational Profiles, supplied by Caris Life Sciences, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/tumor+mutational+profiles/comprehensive+molecular+profiling/pmc12420367-92-2-16
    Average 86 stars, based on 1 article reviews
    tumor mutational profiles - by Bioz Stars, 2026-10
    86/100 stars
    		  Buy from Supplier
    oncocompasstm target cancer mutation profiling liquid kit burning rock biotech n a ddpcrtm supermix for probes  (Bio-Rad)
    99
    Bio-Rad oncocompasstm target cancer mutation profiling liquid kit burning rock biotech n a ddpcrtm supermix for probes
    (A) <t>Mutational</t> frequencies of the top mutated genes identified in the 72 non‐hypermutated gastric cancer (GC) tumors from PRH ( n = 72 for all genes except ARID1A ( n = 62), KMT2D ( n = 70), MYH11 ( n = 63), IRS2 ( n = 65), and CLTCL1 ( n = 61)). (B) Mutational frequencies by anatomical location of non‐hypermutated GC tumors from PRH. For Fundus/Cardia, there were 13 cases, and n = 13 for all genes, except for MYH11 , PHOX2B , and PER1 , which had n = 12. For the Body, there were 45 cases, and all genes had n = 45, except for ARID1A ( n = 38), KMT2D ( n = 43), and CACNA1D ( n = 39). For the Antrum, there were 14 cases, and all genes had n = 14, except for NOTCH1 ( n = 12), CDKN2A ( n = 13), and NFE2L2 ( n = 13).
    Oncocompasstm Target Cancer Mutation Profiling Liquid Kit Burning Rock Biotech N A Ddpcrtm Supermix For Probes, supplied by Bio-Rad, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/tumor+mutational+profiles/Droplet+PCR+Supermix/pmc12147912__mmc2-421-104-121
    Average 99 stars, based on 1 article reviews
    oncocompasstm target cancer mutation profiling liquid kit burning rock biotech n a ddpcrtm supermix for probes - by Bioz Stars, 2026-10
    99/100 stars
    		  Buy from Supplier
    research-grade kits for profiling tumor mutation burden  (Qiagen)
    90
    Qiagen research-grade kits for profiling tumor mutation burden
    (A) <t>Mutational</t> frequencies of the top mutated genes identified in the 72 non‐hypermutated gastric cancer (GC) tumors from PRH ( n = 72 for all genes except ARID1A ( n = 62), KMT2D ( n = 70), MYH11 ( n = 63), IRS2 ( n = 65), and CLTCL1 ( n = 61)). (B) Mutational frequencies by anatomical location of non‐hypermutated GC tumors from PRH. For Fundus/Cardia, there were 13 cases, and n = 13 for all genes, except for MYH11 , PHOX2B , and PER1 , which had n = 12. For the Body, there were 45 cases, and all genes had n = 45, except for ARID1A ( n = 38), KMT2D ( n = 43), and CACNA1D ( n = 39). For the Antrum, there were 14 cases, and all genes had n = 14, except for NOTCH1 ( n = 12), CDKN2A ( n = 13), and NFE2L2 ( n = 13).
    Research Grade Kits For Profiling Tumor Mutation Burden, supplied by Qiagen, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/tumor+mutational+profiles/research+grade+kits+for+profiling+tumor+mutation+burden/10__1158_slash_2159___8290__cd___nb2020___019-3-3-1
    Average 90 stars, based on 1 article reviews
    research-grade kits for profiling tumor mutation burden - by Bioz Stars, 2026-10
    90/100 stars
    		  Buy from Supplier
    mutation profile per tumor  (Johns Hopkins HealthCare)
    90
    Johns Hopkins HealthCare mutation profile per tumor
    (A) <t>Mutational</t> frequencies of the top mutated genes identified in the 72 non‐hypermutated gastric cancer (GC) tumors from PRH ( n = 72 for all genes except ARID1A ( n = 62), KMT2D ( n = 70), MYH11 ( n = 63), IRS2 ( n = 65), and CLTCL1 ( n = 61)). (B) Mutational frequencies by anatomical location of non‐hypermutated GC tumors from PRH. For Fundus/Cardia, there were 13 cases, and n = 13 for all genes, except for MYH11 , PHOX2B , and PER1 , which had n = 12. For the Body, there were 45 cases, and all genes had n = 45, except for ARID1A ( n = 38), KMT2D ( n = 43), and CACNA1D ( n = 39). For the Antrum, there were 14 cases, and all genes had n = 14, except for NOTCH1 ( n = 12), CDKN2A ( n = 13), and NFE2L2 ( n = 13).
    Mutation Profile Per Tumor, supplied by Johns Hopkins HealthCare, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/tumor+mutational+profiles/mutation+profile+per+tumor/pmc04516044-60-60-51
    Average 90 stars, based on 1 article reviews
    mutation profile per tumor - by Bioz Stars, 2026-10
    90/100 stars
    		  Buy from Supplier

    Image Search Results


    (A) Mutational frequencies of the top mutated genes identified in the 72 non‐hypermutated gastric cancer (GC) tumors from PRH ( n = 72 for all genes except ARID1A ( n = 62), KMT2D ( n = 70), MYH11 ( n = 63), IRS2 ( n = 65), and CLTCL1 ( n = 61)). (B) Mutational frequencies by anatomical location of non‐hypermutated GC tumors from PRH. For Fundus/Cardia, there were 13 cases, and n = 13 for all genes, except for MYH11 , PHOX2B , and PER1 , which had n = 12. For the Body, there were 45 cases, and all genes had n = 45, except for ARID1A ( n = 38), KMT2D ( n = 43), and CACNA1D ( n = 39). For the Antrum, there were 14 cases, and all genes had n = 14, except for NOTCH1 ( n = 12), CDKN2A ( n = 13), and NFE2L2 ( n = 13).

    Journal: Cancer Medicine

    Article Title: Actionable Genes and Carcinogenic Pathways for Gastric Cancer in Latinos

    doi: 10.1002/cam4.71216

    Figure Lengend Snippet: (A) Mutational frequencies of the top mutated genes identified in the 72 non‐hypermutated gastric cancer (GC) tumors from PRH ( n = 72 for all genes except ARID1A ( n = 62), KMT2D ( n = 70), MYH11 ( n = 63), IRS2 ( n = 65), and CLTCL1 ( n = 61)). (B) Mutational frequencies by anatomical location of non‐hypermutated GC tumors from PRH. For Fundus/Cardia, there were 13 cases, and n = 13 for all genes, except for MYH11 , PHOX2B , and PER1 , which had n = 12. For the Body, there were 45 cases, and all genes had n = 45, except for ARID1A ( n = 38), KMT2D ( n = 43), and CACNA1D ( n = 39). For the Antrum, there were 14 cases, and all genes had n = 14, except for NOTCH1 ( n = 12), CDKN2A ( n = 13), and NFE2L2 ( n = 13).

    Article Snippet: We examined tumor mutational profiles of GC from 106 PRH between 2015 and 2022 (provided by CARIS Life Sciences and the Precision Oncology Alliance).

    Techniques:

    Frequency of genetic alterations in key signaling pathways in non‐hypermutated gastric cancer cases leading to deregulation of the WNT/β‐catenin, MAPK, PI3K, TGF‐β, and p53 signaling pathways in the non‐hypermutated cases. The frequencies of alterations are expressed as a percentage of all cases. The red color denotes the overall mutational frequency, and blue denotes the amplification frequency for each gene. Figure adapted from: Nature, volume 487, pages 330–337 (2012).

    Journal: Cancer Medicine

    Article Title: Actionable Genes and Carcinogenic Pathways for Gastric Cancer in Latinos

    doi: 10.1002/cam4.71216

    Figure Lengend Snippet: Frequency of genetic alterations in key signaling pathways in non‐hypermutated gastric cancer cases leading to deregulation of the WNT/β‐catenin, MAPK, PI3K, TGF‐β, and p53 signaling pathways in the non‐hypermutated cases. The frequencies of alterations are expressed as a percentage of all cases. The red color denotes the overall mutational frequency, and blue denotes the amplification frequency for each gene. Figure adapted from: Nature, volume 487, pages 330–337 (2012).

    Article Snippet: We examined tumor mutational profiles of GC from 106 PRH between 2015 and 2022 (provided by CARIS Life Sciences and the Precision Oncology Alliance).

    Techniques: Protein-Protein interactions, Amplification